Academician of Engineering proposed minimally invasive treatment plan
The production capacity of florfenicol raw materials is limited or there may be an oversold rebound.
After the Spring Festival, as the veterinary raw material drug market rose to a high level, the market began to weaken, and the veterinary raw material drug market showed a downward trend. However, with the arrival of the peak season for traditional demand, the veterinary raw material drug market may rebound.
Among the Veterinary Raw Materials monitored by the China Veterinary Drug and Feed Trading Center, the market prices of many varieties have dropped significantly.

However, with the advent of summer, the market trend of veterinary drug raw materials may usher in a wave of rebound, and the prices of some products may enter an upward channel.
First, the veterinary raw material drug market is about to enter the peak season of traditional demand, and the downstream market demand is gradually increasing. The rigid demand restricts the downside of the raw material drug market.
Second, the cumulative increase in external factors, environmental protection, security inspections and other factors may cause some companies to restrict or even stop production, and the supply of veterinary raw materials in the veterinary drug market has tightened. The upstream raw material plant of FLORFENICOL has been suspended due to environmental protection. Recently, the news has been released. The florfenicol plant has a high price mentality, and the market has responded positively and focused attention.
Third, the summer high temperature maintenance season is coming. Historical data shows that the high temperature maintenance of mainstream manufacturers will have a greater impact on product market prices.
Fourth, the early-stage demand has weakened, shipments are not smooth, intermediate channels have reduced prices for shipments, withdrawn funds, some channels have been oversold, and inventories have dropped to low levels. Once market demand improves, full replenishment of the industry chain will be triggered, which may be promoted by then Product prices are rising rapidly.
Looking for chemical products? Let suppliers reach out to you!
2026-07-17
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
West Asia Tensions Squeeze Pharma Raw Materials
-
BASF Raises API and Excipient Prices
-
U.S. Onshoring Debate Exposes API Raw-Material Gap
-
Pharmaceutical Tariffs Put Ingredients Back in Focus
-
IPEC Updates Excipient Qualification Guidance
-
McKinsey Pays to Close a Purdue Liability Chapter
-
AstraZeneca India Eyes ₹3,400 Crore Bengaluru Sale
-
Iran Conflict Leaves a Long Shadow on Drug Supply
-
Sun Pharma’s Organon Bid Would Redraw Indian Pharma M&A
-
Amazon Turns Lilly’s Weight-Loss Pill Into a Retail Logistics Play
Recommend Reading
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Roche Keeps German Diagnostics Investment
-
Parliamentary Panel Urges Expanded Price Controls as Dozens of Cancer Drugs Remain Unregulated
-
India Raises Cancer Drug Price Caps by 50%
-
Premium Global Chemical Sourcing Requests (3-7 Jan, 2026)
-
Maintenance Concentration Leads to Cost Decline; April PP Market Experiences Volatile Performance
-
Traditional Peak Season Arrives, Palm Oil Prices Expected to Rise in China
-
On April 29, the market price of pure benzene in China was slightly increased
-
Supply and Demand Drag Down Methylene Chloride in a Cliff-like Decline